Term: tremelimumab

Pronunciation: (treh-meh-LIM-yoo-mab)

Description:

A drug that binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat different types of cancer. Tremelimumab is used with durvalumab to treat adults with hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery. It is also used with durvalumab and platinum chemotherapy to treat adults with non-small cell lung cancer that has spread to other parts of the body and does not have an abnormal EGFR or ALK gene. It is also being studied in the treatment of other types of cancer. Tremelimumab may block CTLA-4 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Imjudo.